In summary, our new preclinical mouse model will help the lung cancer community to develop and test in vivo new therapeutic options for patients with EGFR-mutated lung cancer who relapse after osimertinib-based therapy due to the appearance of MET amplification, for instance, the bispecific antibody amivantamab against EGFR and MET [17]. This evidence concerns the gene MET and lung carcinoma.